Ct And Ng Testing Market Size 2025-2029
The ct and ng testing market size is valued to increase by USD 883.4 million, at a CAGR of 8.4% from 2024 to 2029. Increasing prevalence of Ct and Ng infections will drive the ct and ng testing market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 41.4% growth during the forecast period.
- By Product - Assays and kits segment was valued at USD 1.20 billion in 2023
- By Test - Lab tests segment accounted for the largest market revenue share in 2023
Market Size & Forecast
- Market Opportunities: USD 1.37 billion
- Market Future Opportunities: USD 883.4 million
- CAGR from 2024 to 2029 : 8.4%
Market Summary
- The Ct and Ng testing market is defined by the critical need for accurate and timely detection of two of the most prevalent sexually transmitted infections (stis). Growth is fueled by the high incidence of chlamydia trachomatis and neisseria gonorrhoeae, particularly asymptomatic infections that demand robust screening programs to prevent severe health complications.
- Key technological drivers include the widespread adoption of molecular diagnostic techniques, especially nucleic acid amplification tests (naats), which offer superior diagnostic accuracy over traditional methods. The evolution of these technologies has led to the development of multiplex assays and automated molecular systems, enhancing laboratory efficiency.
- A significant trend is the expansion of point-of-care (poc) testing, which enables same-visit diagnosis and immediate treatment, addressing the persistent issue of patient loss to follow-up. For instance, a clinic implementing rapid molecular diagnostics can reduce diagnostic turnaround time from days to under an hour, directly improving patient management and public health outcomes.
- However, the market faces challenges from the high cost of advanced tests, which can limit access in resource-limited settings, and the growing threat of antimicrobial resistance (amr), which complicates treatment and heightens the need for advanced genotypic resistance testing.
What will be the Size of the Ct And Ng Testing Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Ct And Ng Testing Market Segmented?
The ct and ng testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Product
- Assays and kits
- Instruments and analyzers
- Test
- Lab tests
- PoC tests
- End-user
- Diagnostic laboratories
- Hospitals and clinics
- Public health agencies and NGOs
- Others
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Product Insights
The assays and kits segment is estimated to witness significant growth during the forecast period.
The assays and kits segment is fundamental to the ct and ng testing market, comprising consumables for molecular diagnostics. This category is shifting from single-target tests to comprehensive syndromic sti panels that enhance pathogen identification.
Innovations focus on improving reagent stability and streamlining the sample preparation workflow, enabling integration with automated laboratory information systems (lims).
These advanced kits, which support techniques from serological detection to next-generation sequencing, are crucial for reducing diagnostic turnaround time and addressing patient loss to follow-up.
Integrated assay designs have demonstrated the ability to reduce manual processing steps by over 30%, improving overall lab throughput and consistency in results for chlamydia trachomatis and other sexually transmitted infections (stis).
The Assays and kits segment was valued at USD 1.20 billion in 2023 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 41.4% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Ct And Ng Testing Market Demand is Rising in North America Request Free Sample
The geographic landscape of the market is diverse, with North America representing a 41.4% share of the opportunity, driven by a sophisticated healthcare infrastructure and high adoption of advanced diagnostics.
In this region, there is a strong focus on workflow consolidation and clinical sample processing efficiency.
In contrast, Asia is the fastest-growing region, where the focus is on expanding access through high-throughput screening and the adoption of non-invasive sample types like urine, which shows over 95% urine sample compatibility with leading molecular tests.
The use of self-collected vaginal swabs is also increasing patient compliance. Technologies like digital pcr are emerging for precise pathogen identification, while established methods ensure high clinical sensitivity.
This regional divergence highlights different strategic priorities, from optimizing mature systems to building foundational diagnostic capacity.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The strategic direction of the market is increasingly focused on deploying rapid molecular diagnostics for stis to improve public health outcomes. The adoption of point-of-care naat for ct/ng is pivotal, enabling immediate clinical decisions and reducing transmission risks.
- This is complemented by the development of multiplex pcr for comprehensive sti panels, which offer a more complete diagnostic picture from a single sample and improve the cost-effectiveness of multiplex sti assays. A key focus is on ct/ng testing in asymptomatic populations, where early detection is critical.
- The integration of digital health in sti testing, particularly through home collection kits for ct/ng analysis, is breaking down barriers to access. Meanwhile, automated platforms for high-throughput sti testing are essential for large-scale screening programs managed by public health agencies.
- These advances in naat technology for ct/ng must be weighed against challenges in implementing poc testing for stis, including logistical hurdles and quality control. The impact of amr on gonorrhea treatment protocols is a severe concern, driving demand for tests that support antimicrobial resistance surveillance in ng.
- Innovations are also improving diagnostic accuracy for chlamydia through better validation of self-collected swabs for naats and more effective ct/ng co-infection diagnostic methods. These molecular vs culture methods for gonorrhea offer a significant reduction in turnaround time, with some automated systems processing samples up to 50% faster than manual workflows.
What are the key market drivers leading to the rise in the adoption of Ct And Ng Testing Industry?
- The increasing global prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections stands as a primary and most significant driver for the testing market.
- Market growth is fundamentally driven by technological advancements and urgent public health needs. The superior diagnostic accuracy of nucleic acid amplification tests (naats) in detecting bacterial genetic material has made them the standard for diagnosing neisseria gonorrhoeae and other pathogens.
- The development of fully automated molecular systems enhances laboratory efficiency, allowing a high-throughput laboratory to increase its testing capacity by over 50%. These platforms support screening program effectiveness by delivering reliable results at scale.
- The integration of sophisticated diagnostic algorithm integration into clinical decision support tools further refines testing strategies, ensuring that diagnostics directly contribute to better patient management and disease control efforts.
What are the market trends shaping the Ct And Ng Testing Industry?
- The expansion of point-of-care molecular diagnostics represents a significant market trend, driven by the imperative to provide rapid, accurate results for same-visit diagnosis and treatment.
- Key trends are reshaping the delivery of diagnostic services for sexually transmitted infections (stis). The expansion of point-of-care (poc) testing is a primary trend, with decentralized testing models improving patient compliance by enabling same-visit diagnosis. This approach has been shown to increase treatment initiation by up to 60% in certain clinical settings.
- Concurrently, the integration of at-home sample collection with telemedicine consultations is broadening access to testing for chlamydia trachomatis, removing barriers related to privacy and convenience. Innovations in molecular diagnostic techniques are leading to more sophisticated multiplex assays that can detect multiple pathogens from a single sample, improving efficiency. These developments are creating a more patient-centric diagnostic ecosystem.
What challenges does the Ct And Ng Testing Industry face during its growth?
- A substantial challenge affecting market growth is the pervasive lack of awareness regarding infections, coupled with the significant social stigma associated with sexually transmitted infections.
- Persistent challenges constrain market expansion, particularly the threat of antimicrobial resistance (amr) in neisseria gonorrhoeae, which complicates treatment and necessitates advanced molecular diagnostics like genotypic resistance testing. However, the high cost of real-time pcr platforms and reagents creates significant barriers in resource-limited settings, where diagnostic infrastructure is often lacking.
- The high prevalence of asymptomatic infections means that many cases go undetected, undermining public health surveillance and contact tracing protocols. Establishing robust quality assurance programs and navigating the complex regulatory approval process for new tests further add to the operational hurdles, with development costs for a novel assay sometimes being 25% higher than anticipated.
Exclusive Technavio Analysis on Customer Landscape
The ct and ng testing market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the ct and ng testing market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Ct And Ng Testing Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, ct and ng testing market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - Offers advanced molecular diagnostic solutions, featuring Ct and Ng assays integrated with automated platforms designed for high-throughput clinical laboratory environments.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Abbott Laboratories
- Aptitude Medical Systems Inc.
- Becton Dickinson and Co.
- binx health Inc.
- Bio Rad Laboratories Inc.
- Cepheid Inc.
- DiaSorin SpA
- ELITechGroup SAS
- F. Hoffmann La Roche Ltd.
- GeneProof
- Hologic Inc.
- LetsGetChecked
- Meridian Bioscience Inc.
- Promega Corp.
- QIAGEN N.V.
- Seegene Inc.
- Thermo Fisher Scientific Inc.
- VIRCELL S.L.
- Visby Medical Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Ct and ng testing market
- In May 2025, a leading diagnostics firm launched its next-generation rapid molecular point-of-care system, designed for comprehensive STI panels including Ct/Ng, featuring enhanced connectivity for seamless integration with electronic health records.
- In April 2025, a prominent global telehealth provider announced a major expansion of its at-home STI testing program, incorporating advanced molecular assays for Ct/Ng, making the service available in several new international markets.
- In March 2025, a major diagnostics company received regulatory clearance for its expanded multiplex molecular STI panel, which includes a broader range of bacterial and viral pathogens alongside Ct/Ng, designed to provide a more holistic diagnostic profile from a single sample.
- In February 2025, a prominent medical device company gained regulatory approval for its novel molecular point-of-care Ct/Ng test, which provides highly accurate results in under 30 minutes, facilitating same-visit diagnosis and treatment.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Ct And Ng Testing Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 292 |
| Base year | 2024 |
| Historic period | 2019-2023 |
| Forecast period | 2025-2029 |
| Growth momentum & CAGR | Accelerate at a CAGR of 8.4% |
| Market growth 2025-2029 | USD 883.4 million |
| Market structure | Fragmented |
| YoY growth 2024-2025(%) | 7.9% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, UAE, Brazil, South Africa, Saudi Arabia and Turkey |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The market for ct and ng testing is undergoing a significant transformation, driven by advancements in molecular diagnostics that prioritize speed and diagnostic accuracy. The industry has moved decisively toward nucleic acid amplification tests (naats) as the standard, with a focus on detecting bacterial genetic material from non-invasive sample types.
- This shift addresses the high prevalence of asymptomatic infections, a critical factor in the transmission of chlamydia trachomatis and neisseria gonorrhoeae. Boardroom decisions are increasingly centered on investing in multiplex assays and automated molecular systems to capture efficiencies in high-throughput screening environments.
- For instance, integrated platforms have demonstrated the ability to improve laboratory workflows by consolidating the sample preparation workflow, leading to a 40% reduction in hands-on time. The growing threat of antimicrobial resistance (amr) is fueling R&D in genotypic resistance testing and next-generation sequencing for enhanced pathogen identification.
- Furthermore, the expansion of point-of-care (poc) testing and digital pcr reflects a strategic push toward decentralized diagnostics, requiring careful consideration of reagent stability and clinical sensitivity to ensure reliable performance outside traditional lab settings.
What are the Key Data Covered in this Ct And Ng Testing Market Research and Growth Report?
-
What is the expected growth of the Ct And Ng Testing Market between 2025 and 2029?
-
USD 883.4 million, at a CAGR of 8.4%
-
-
What segmentation does the market report cover?
-
The report is segmented by Product (Assays and kits, and Instruments and analyzers), Test (Lab tests, and PoC tests), End-user (Diagnostic laboratories, Hospitals and clinics, Public health agencies and NGOs, and Others) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Increasing prevalence of Ct and Ng infections, Lack of awareness and stigma
-
-
Who are the major players in the Ct And Ng Testing Market?
-
Abbott Laboratories, Aptitude Medical Systems Inc., Becton Dickinson and Co., binx health Inc., Bio Rad Laboratories Inc., Cepheid Inc., DiaSorin SpA, ELITechGroup SAS, F. Hoffmann La Roche Ltd., GeneProof, Hologic Inc., LetsGetChecked, Meridian Bioscience Inc., Promega Corp., QIAGEN N.V., Seegene Inc., Thermo Fisher Scientific Inc., VIRCELL S.L. and Visby Medical Inc.
-
Market Research Insights
- Market dynamics are shaped by the strategic shift toward decentralized testing models to improve patient outcomes. The adoption of platforms enabling same-visit diagnosis has been shown to reduce patient loss to follow-up by over 30%, directly impacting public health surveillance and containment efforts.
- The integration of at-home sample collection with telemedicine consultations is expanding access, with some digital health services reporting a 50% increase in testing uptake among younger demographics who might otherwise avoid clinical visits. This is supported by an evolving healthcare infrastructure that increasingly incorporates laboratory information systems (lims) and clinical decision support tools.
- These systems are essential for managing data from widespread screening program effectiveness and facilitating timely contact tracing protocols, ultimately enhancing the overall efficiency of public health responses to STIs.
We can help! Our analysts can customize this ct and ng testing market research report to meet your requirements.